Skip to main content

NeuBase Therapeutics, Inc.

NBSEDelisted May 16, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001173281

NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.

13F holders, Q2 2024

Institutional positions in NeuBase Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

NBSE is no longer listed, and 13F filings after Q1 2024 list far fewer holders. See Q1 2024

Institutional holders
2
−16 vs. Q1 2024
Shares held
16.1K
−377.3K (−95.9%) vs. Q1 2024
Total value
$4.95K
−$172.1K (−97.2%) vs. Q1 2024
New holders
1
0 more added
Sold out
17
1 more reduced

Compare with Q1 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting NBSE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2024: 2 institutions
Q1 2021: 57 institutionsQ2 2021: 59 institutionsQ3 2021: 48 institutionsQ4 2021: 46 institutionsQ1 2022: 45 institutionsQ2 2022: 43 institutionsQ3 2022: 44 institutionsQ4 2022: 35 institutionsQ1 2023: 36 institutionsQ2 2023: 26 institutionsQ3 2023: 20 institutionsQ4 2023: 21 institutionsQ1 2024: 18 institutionsQ2 2024: 2 institutionsQ3 2024: 0 institutionsQ4 2024: 0 institutionsQ1 2025: 0 institutionsQ2 2025: 0 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ2 2024: $4.95K
Q1 2021: $59.4MQ2 2021: $51.5MQ3 2021: $36.6MQ4 2021: $31.6MQ1 2022: $23.3MQ2 2022: $13.4MQ3 2022: $4.74MQ4 2022: $1.94MQ1 2023: $1.72MQ2 2023: $1.08MQ3 2023: $301.2KQ4 2023: $340.2KQ1 2024: $177.1KQ2 2024: $4.95KQ3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding NBSE and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 20250$0
Q1 20250$0
Q4 20240$0
Q3 20240$0
Q2 20242$4.95K
Q1 202418$177.1K
Q4 202321$340.2K
Q3 202320$301.2K
Q2 202326$1.08M
Q1 202336$1.72M
Q4 202235$1.94M
Q3 202244$4.74M
Q2 202243$13.4M
Q1 202245$23.3M
Q4 202146$31.6M
Q3 202148$36.6M
Q2 202159$51.5M
Q1 202157$59.4M

Institutions, Q2 2024

Shares, value and share of portfolio for each institution holding NeuBase Therapeutics, Inc.; share changes are against Q1 2024.

Institutions holding NBSE in Q2 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Baader Bank INC16,089$4.95K0.00%+16,089New
Advisor Group Holdings, Inc.1$00.00%−21−95.5%Reduced
DME Capital Management, LPSuperinvestorGreenlight Capital0$00.00%−136,350−100.0%Sold out
Renaissance Technologies LLC0$00.00%−88,229−100.0%Sold out
Point72 Asset Management, L.P.0$00.00%−62,500−100.0%Sold out
Carnegie Mellon University0$00.00%−46,970−100.0%Sold out
Vanguard Group Inc0$00.00%−18,981−100.0%Sold out
Prelude Capital Management, LLC0$00.00%−15,550−100.0%Sold out
Geode Capital Management, LLC0$00.00%−15,482−100.0%Sold out
UBS Group AG0$00.00%−4,056−100.0%Sold out
Tower Research Capital LLC (TRC)0$00.00%−2,572−100.0%Sold out
Cubist Systematic Strategies, LLC0$00.00%−1,251−100.0%Sold out
Bank of America Corp0$00.00%−804−100.0%Sold out
First Manhattan Co0$00.00%−353−100.0%Sold out
Wells Fargo & Company0$00.00%−79−100.0%Sold out
The PNC Financial Services Group, Inc.0$00.00%−21−100.0%Sold out
Newbridge Financial Services Group, Inc.0$00.00%−12−100.0%Sold out
Morgan Stanley0$00.00%−9−100.0%Sold out
Royal Bank of Canada0$00.00%−153−100.0%Sold out